Cilengitide: an RGD pentapeptide αανν&bgr;β3 and αανν&bgr;β5 integrin inhibitor in development for glioblastoma and other malignancies

Author： Reardon David A Neyns Bart Weller Michael Tonn Joerg Christian Nabors Louis Burt Stupp Roger

Publisher： Future Medicine

ISSN： 1479-6694

Source： Future Oncology, Vol.7, Iss.3, 2011-03, pp. : 339-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TGF-&bgr;β in cancer and other diseases

By Neil Jason R Galliher Amy J Schiemann William P

Future Oncology, Vol. 2, Iss. 2, 2006-04 ,pp. : 185-189

Future Medicine

Access to resources Recommend Favorite

Mechanisms of the epithelial––mesenchymal transition by TGF-&bgr;β

By Wendt Michael K Allington Tressa M Schiemann William P

Future Oncology, Vol. 5, Iss. 8, 2009-10 ,pp. : 1145-1168

Future Medicine

Access to resources Recommend Favorite

&bgr;β-thymosins in cancer: implications for the clinic

By Freeman Kevin W Banyard Jacqueline

Future Oncology, Vol. 5, Iss. 6, 2009-08 ,pp. : 755-758

Future Medicine

Access to resources Recommend Favorite

Wnt/&bgr;β-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology

By Cavard Catherine Colnot Sabine Audard Virginie Benhamouche Samira Finzi Laetitia Torre Cyril Grimber Gisèèle Godard Céécile Terris Benoit Perret Christine

Future Oncology, Vol. 4, Iss. 5, 2008-10 ,pp. : 647-660

Future Medicine

Access to resources Recommend Favorite

PKM2: a new player in the &bgr;β-catenin game

By Canal Frédéric Perret Christine

Future Oncology, Vol. 8, Iss. 4, 2012-04 ,pp. : 395-398

Future Medicine

Access to resources Recommend Favorite